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Neuropathy, Retinopathy, and
Glucose-Lowering Treatments
ZACHARY T. BLOOMGARDEN, MD
T
his is the seventh of a series of arti-
cles based on presentations at the
American Diabetes Association
(ADA) Scientiﬁc Sessions held 5–9 June
2009 in New Orleans, Louisiana. This in-
stallment pertains to neuropathy, reti-
nopathy, and a number of innovative
potential glucose-lowering therapies.
Neuropathy
Many studies presented at the American
Diabetes Association (ADA) Scientiﬁc
Sessions addressed aspects of neurologic
disordersindiabetes.Brazaetal.(abstract
569)foundthat19%of76type2diabetic
persons receiving metformin for 1 year
had vitamin B12 levels 250 ng/ml, and
23% had levels 250–400 ng/ml. (Ab-
stract numbers refer to the Abstracts of
the 69th Scientiﬁc Sessions of the Ameri-
can Diabetes Association, Diabetes, Vol.
58,Supplement1,2009.)Peripheralneu-
ropathy was present in 77 and 23% of
thesegroups,respectively,andwasfound
in 7% of those with normal B12 levels.
Deﬁciency correlated neither with dura-
tion of metformin use nor with erythro-
cyte macrocytosis.
Abra ˜o et al. (abstract 121) found that
diabetic persons with periodontal disease
or edentulism were 8.1-fold more likely
to have loss of sensation to the Semmes-
Weinstein10-gmonoﬁlament.Ismailand
Venkatesan (abstract 28-LB) found that
diabetic versus nondiabetic persons had
94% versus 18% prevalence of sensori-
neural hearing loss, with mild-to-
moderate hearing loss in 40% of diabetic
persons with A1C 7% but in 56% of
those with higher A1C levels, although
noting that their ﬁndings might be ex-
plained by age differences. Bainbridge
and Cowie (abstract 957) found that,
among 472 diabetic participants in the
National Health and Nutrition Examina-
tion Survey (NHANES), hearing impair-
ment occurred 5.6, 5.8, and 2.7 times
more often in persons with peripheral
neuropathy, with coronary disease, and
with A1C 7% than in those not having
these characteristics.
Ryanetal.(abstract101-LB)reported
neuropsychological test results in 393
nondiabetic and 142 diabetic persons
from 11 general medical practices, ﬁnd-
ing that 36.4% versus 45.1% had mild
cognitive impairment and 3.6% versus
4.2% had dementia. Hypertension, coro-
naryarterydisease,andhypercholesterol-
emia were not related to risk of cognitive
dysfunction. Silverstein et al. (abstract
130)administeredthenoncompetitiveN-
methyl-D-asparate receptor antagonist
used for treatment of Alzheimer’s disease
immediately after subjecting rats to glu-
cose 10–15 mg/dl for 90 min; compared
with untreated rats, hypoglycemia-
induced cortical neuronal damage de-
creased 35%.
Maue ´s et al. (abstract 1,302) found
that among 11, 28, and 29 nonobese men
with no, mild, and moderate/severe ob-
structive sleep apnea on polysomnogra-
phy, respectively, the latter group had a
68% increase in fasting plasma insulin
and a 94% increase in HOMA-IR over the
former, with impaired glucose tolerance
in 21%. Simmons and Shaw (abstract
997) reported that, among 1,454 persons
in a population survey, the red cell count
washigherinthosewithnewlydiagnosed
diabetes or IFG/IGT than in those with
normal glucose tolerance, potentially re-
ﬂecting nocturnal hypoxia from sleep-
disordered breathing. Cigarette use was
associated with higher hemoglobin but
not with an increase in red cell count.
Thosewithknowndiabeteshadlowerred
cellcount,whichtheauthorsexplainedas
reﬂecting chronic kidney disease. Aron-
sohn et al. (abstract 684) found an apnea-
hypopnea index of 5/h on overnight
polysomnography in 47 of 54 type 2 dia-
betic persons, with mean A1C 6.0%,
7.7%, and 8.2% in those with no, mild-
moderate, and severe obstructive sleep
apnea. Maser et al. (abstract 831), how-
ever, found that a measure of autonomic
neuropathy improved in nondiabetic but
not in diabetic persons with sleep-
disordered breathing after a 6-week pe-
riod of continuous positive airways
pressure nocturnal treatment.
Etropolski et al. (abstract 852) ad-
ministered an extended-release form of
the dual -opioid receptor agonist/
norepinephrinereuptakeinhibitortapen-
tadol, structurally similar to tramadol, to
588 patients with moderate-to-severe
pain from diabetic peripheral neuropa-
thy. The 392 patients who responded
were randomized to active drug versus
placebo for 12 weeks, with pain symp-
toms redeveloping in the placebo group.
Side effects, however, included nausea,
dizziness, somnolence, and constipation,
leading to one-third discontinuing in the
open-labelphaseandto15%versus8%of
the placebo group discontinuing during
the controlled phase of the study.
The neuropathic foot
JamesA.Birke(BatonRouge,LA)gavethe
Roger Pecoraro Lecture on the legacy of
the National Hansen’s Disease Center
(Carville, LA) in the care of the neuro-
pathicfoot.PersonswithHansen’sdisease
were forcibly quarantined at the Louisi-
ana Leper Home in the 1890s, as the dis-
ease was essentially incurable until the
ﬁrstusesofsulfonedrugsinthe1940s.In
1966 Dr. Paul Brand became the director
of the rehabilitation program at the cen-
ter, bringing out the then novel concept
that repetitive walking stress was the pri-
mary cause of plantar ulceration and
faultyhealingintheinsensatefoot,imply-
ing a new approach to development of
therapeutic approaches based on under-
standing the mechanisms of injury. Ani-
mal studies showed that local
hyperthermia often appeared prior to
other evidence of injury, suggesting an
important approach to diagnosis. Ap-
proaches to reducing injury, particularly
the use of casting and subsequent use of
specialfootwear,wereusedindeveloping
treatments.Treatmentofdiabeticpatients
at the Carville center began in the 1970s,
withevidencethathealingratesweresim-
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ease, contributing to the development of
multidisciplinary lower-extremity ampu-
tation prevention (LEAP) programs. Ap-
proaches included annual foot screening
with the 10-g monoﬁlament to discrimi-
nate between persons at risk and those
notatrisk(1),ongoingpatienteducation,
scheduled follow-up based on risk, assis-
tance for patients to obtain protective
footwear, and providing easy access to
prompt management of foot problems.
The Carville foot screen was adapted
to provide four risk categories: 0 (no loss
of protective sensation), 1 (loss of protec-
tive sensation), 2 (loss of protective sen-
sation with either pressure callus/
deformity or poor circulation), and 3
(history of plantar ulcer, Charcot foot or
amputation). The essentials of patient ed-
ucation are straightforward: daily foot
checking, promptly calling for examina-
tion with new injury, never walking bare-
foot or on stocking feet (even to the
bathroomatnight),andwearingonlypre-
scribed footwear, breaking in new shoes
slowly. Birke recommended using simple
devices such as soft insoles and molded
depth-inlay shoes, and, when needed,
walking casts, wedge shoes, and accom-
modative dressings (which he termed
“our greatest things”), suggesting that we
pay attention to patients’ wishes for rela-
tively standard-appearing footwear. “Af-
ter [ulcers] close, the challenge is to keep
them closed,” he said, using plantar tem-
perature measurement to determine areas
at particular risk, and gradually increas-
ingactivitywithappropriatefootwear.Al-
ternativemethodstowalkingcasts,which
similarly result in healing of 90% of ul-
cers at 6 weeks, include felt relief pads,
walking splints, and “healing shoes.”
Such approaches have led to reduction in
ulcers and hospitalizations, with conse-
quent reduction in cost. Birke reminded
the audience that Dr. Brand, referring
to the terrible burden of the insensitive
foot,termedpain“thegiftnobodywants,”
and that his approach was to treat “the
neuropathic foot [as] a matter of mechan-
ics, not medicine.”
Gastroparesis
Niels Ejskjaer (Aarhus, Denmark) re-
viewed the diagnosis and treatment of di-
abetic gastroparesis, suggesting that there
are limits in the standard deﬁnition of de-
layed gastric emptying in the absence of
mechanical obstruction. Indeed, al-
though some studies suggest that about
half of type 1 diabetic persons have evi-
dence of the condition (2), other studies
show, paradoxically, that fewer than half
of diabetic persons with symptoms com-
patible with gastroparesis, such as early
satiety, pain, bloating, nausea, and vom-
iting, have evidence of delayed gastric
emptying. Ejskjaer noted that poor glyce-
mic control may be the only sign in some
patients, although hyperglycemia in itself
will delay gastric emptying (3), leading to
an indeterminate direction of causality.
Severecasesmayleadtoweightloss,elec-
trolyte derangement, and recurrent
swings between ketoacidosis and hypo-
glycemia. Gastroparesis may also be asso-
ciated with dysmotility of the esophagus,
gallbladder, and biliary tract, and with
pancreatic exocrine dysfunction and noc-
turnal diarrhea. Diagnosis requires care-
ful history, examination, endoscopy, and
gastric emptying tests in excluding other
causes. Gastroparesis may be brought
about by a combination of autonomic
neuropathy, glucose toxicity, connective
tissue degeneration, advanced glycation
end product (AGE) formation, and per-
haps autoimmunity. There is histological
evidence of smooth muscle degeneration
and ﬁbrosis as well as of abnormal vagal
nerve ﬁber density in gastroparesis (4),
suggesting elements of both gastromy-
opathy and neuropathy in the condition.
In a study comparing 15 type 1 diabetic
patients with 12 normal control subjects,
an endoscopic technique found increased
pain threshold in diabetic patients, but
larger referred pain areas from such stim-
uli, suggesting central neuronal changes
in the pathophysiology of diabetic gastro-
paresis, evidence of involvement of a
“third neuron” in the brainstem and thal-
amus (5). Gastric emptying tests include
scintigraphy and ultrasound, giving
information more about retention than
emptyingofgastriccontents,andelectroga-
strography and breath and paracetamol
(acetaminophen) tests.
Thereisconsiderableinterestinphar-
macologic treatment approaches. A num-
ber of prokinetic agents have been
usedforthetreatmentofgastroparesis,in-
cludingdopaminergicantagonistssuchas
metoclopramideanddomperidone;moti-
lin agonists such as erythromycin; the se-
rotonergic agonists cisapride, tegaserod,
renzapride, mosapride, and ATI-7505;
the muscarinic agonist bethanechol; the
acetyl cholinesterase inhibitors phy-
sostigmine and neostigmine; the H2 re-
ceptor antagonist nizatidine LR; the
cholecystokinin receptor antagonists
loxiglumide and dexloxiglumide; the
opiodreceptorantagonistalvimopan;and
a number of ghrelin receptor agonists.
Ghrelin is a 28-amino acid peptide pro-
duced in the gastric mucosa, with a num-
ber of studies showing an effect in
increasing gastric emptying. Ejskjaer re-
viewed his study of ten patients treated
with a ghrelin receptor agonist, with gas-
tricemptyingnormalizedinthreeandsig-
niﬁcant improvement of emptying in all,
and a mean 37% decrease in the severity
of postprandial fullness (6). A number of
surgicaltreatmentsarealsoused.Gastros-
tomy can be performed endoscopically,
while jejeunostomy, requiring surgical
placement, may be more effective, al-
though still associated with very high
complication rates due in large part to the
severityofunderlyingillnessofmanyper-
sons with the condition (7). Total paren-
teral nutrition is occasionally needed but
may be associated with adverse outcome
as well (8). Gastrectomy, pyloroplasty,
and gastrojejeunospomy have also been
used. Gastric pacing may lead to im-
proved outcome, reducing the require-
ment for parenteral nutrition and
hospitalization(9).Ejskjaer’sstudieshave
shown improvement in symptoms at 1
and2years,althoughwithoutevidenceof
improvedgastricmotility,contractility,or
function.
Peripheral neuropathy
David N. Herrmann (Rochester, NY) dis-
cussed diabetic sensory neuropathy, re-
viewing the classiﬁcation of peripheral
sensory ﬁbers into large myelinated
A-/, smaller myelinated A-, and un-
myelinated C ﬁbers serving mainly noci-
ceptive sensations. Nerve conduction
studies measure function of the myelin-
ated ﬁbers. Different patterns of distal
sensory neuropathy may be seen, with
small ﬁber neuropathy associated with
pain, dysesthesia, and paresthesia, typi-
cally with physical ﬁndings restricted to
mild pin or thermal sensation loss and
with normal electrophysiological tests,
while large ﬁber loss leads to tight,
wrapped band-like sensations, abnormal
electrophysiological tests, impairment of
vibration and proprioceptive sensation,
loss of reﬂexes, and positive Rhomberg
sign or ataxic gait. Often there is a mixed
presentation with abnormalities of both
small and large ﬁbers.
The classic staging system of diabetic
distal symmetric polyneuropathy ranges
from asymptomatic mild ﬁndings to in-
creasing degrees of symptomatic neurop-
athy, but this relies particularly on
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plantar nerve action potential measure-
ment (10) may detect early distal large
ﬁber involvement, but there is a promi-
nent age effect, the studies are technically
difﬁcult, and local foot trauma may lead
toabnormalities.Inastudyof108control
subjects and 133 patients with clinical
distal sensory neuropathy, using age-
based normative data, sural nerve poten-
tial was abnormal in only 27% of persons
with large ﬁber neuropathy and in 9%
with small ﬁber neuropathy, while the
medial plantar nerve action potential was
abnormal in 69 and 11%, respectively.
Other medial plantar nerve conduction
studies suggest that this is a reproducible
test that may be more useful than sural
nerve conduction studies in persons with
mild symptomatic diabetic neuropathy
(11).
Approaches with evaluation of both
small and large ﬁbers may allow earlier
recognition of diabetic peripheral neu-
ropathy, perhaps improving selection of
persons for clinical trials. Herrmann
noted that studies of persons with more
advanced disease may address a popula-
tion with irreversible damage. Diabetic
persons previously thought not to have
neuropathy may have subtle abnormali-
ties with patch skin biopsy, which allows
immunohistochemical staining of epider-
mal nerve ﬁbers to measure ﬁber density
andtoexaminemorphologicalabnormal-
ities, a measure of small nerve ﬁbers
(12,13). Such studies compare favorably
with nerve conduction measurement in
assessment of diabetic neuropathy (14),
and may show greater sensitivity than
sural nerve biopsy in the measurement of
peripheral small ﬁber loss (15), correlat-
ingwithclinicalneuropathyseverity(16).
The medial plantar nerve action potential
becomes abnormal later than skin biopsy
in persons with normal routine nerve
conductionstudies(17),withskinbiopsy
nerve ﬁber density potentially having a
role in early diagnosis of diabetic periph-
eral neuropathy (18). Another approach
to early diagnosis is the use of confocal
microscopy to show evidence of corneal
denervation (19).
Pathogenesis of neuropathy
Angelika Bierhaus (Heidelberg, Ger-
many)discussedinﬂammationindiabetic
neuropathy, noting the importance of
pain in the recognition of heat, cold, and
inﬂammation, with well-recognized mo-
lecularmechanisms,butpointingoutthat
pain also occurs in a variety of metabolic
disturbances, in particular diabetes, with
uncertain mechanisms. Hyperglycemia
appears to be related to the development
ofpain,butevidencethatimprovementof
glycemia reduces such symptoms is lack-
ing, suggesting that other factors may be
involved. It is interesting that pain and
dysesthesias may precede the develop-
ment of type 2 diabetes, and that with
hyperglycemia or elevated free fatty acid
levels there is increased ﬂux through the
mitochondrial respiration chain leading
to increased oxidant stress, with elevated
levels of superoxide production, and a
consequentincreaseinproductionofme-
tabolites such as dihydroxyacetone phos-
phate, which is converted into the AGE
precursormethylglyoxal(MG).Anumber
of factors increase MG production, which
directly and via its metabolites may pro-
duce vascular and neuronal inﬂamma-
tion, in part involving prostaglandin E2
and nuclear factor (NF)-B (20). MG is
physiologically degraded by glyoxalase
(GLO)-1 and -2, reduced activity of
which will increase AGE production,
leadingBierhaustosuggestthatthelossof
these MG-detoxifying mechanisms may
contribute to diabetic neuropathy. She
pointed out that a compound similar to
MG is present in horseradish and wasabi,
resulting in the “burning” taste associated
with these two foods, and this may be rel-
evant to some symptoms of painful
neuropathy.
StudiesofthenematodeCaenorhabdi-
tis elegans overexpressing the homolog of
GLO show reduction in damage associ-
ated with elevated glucose levels, leading
toincreasedlifespanandtopreventionof
neuronaldamage(21).Inamousemodel,
diabetes was associated with a reduction
in GLO activity and an increase in MG
levels.SciaticnerveGLOactivitywaspar-
ticularly low, even more so in diabetic
mice, suggesting greater risk of AGE ac-
cumulationinperipheralnerves.Inanan-
imal model, diabetes decreased GLO to a
level similar to that in mice with one copy
of an inactive gene, with increased MG
levels,andevidenceofhyperalgesiawitha
“hotplate” stimulus. A GLO inhibitor also
increased MG levels and led to hyperalge-
sia, while GLO overexpression reduced
hyperalgesia. It appears that a voltage-
gated sodium channel, Nav1.8, plays a
role in the increased pain response, and
that inhibiting the sodium channel with
ambroxol or reducing expression of
Nav1.8 reduced the degree of MG-
dependent hyperalgesia. MG binds to ar-
ginine residues in Nav1.8, opening the
channel and leading to greater pain per-
ception, suggesting potential therapeutic
approaches. In a pilot study, plasma MG
levels were higher in diabetic persons
with painful neuropathy.
The accumulation of MG leads to in-
creased AGE formation (22) and to
NF-B activation with loss of neuronal
function (23,24). Interestingly, receptor
for AGE (RAGE) deﬁciency partially pro-
tectsmicefromdiabetes-mediatedinhibi-
tion of GLO-1 expression and
neuropathic pain. Bierhaus concluded
that there is a relationship of MG with
paininearlydiabetesandwithlossofpain
perception in the later stages of diabetic
neuropathy.
Retinopathy
Several studies presented at the ADA
meeting addressed aspects of diabetic ret-
inopathy. Gong et al. (abstract 97) pre-
sentedmicrovascularoutcomeresultsofa
20-year follow-up of 566 of the original
577 participants in the Chinese Da Qing
study of lifestyle intervention for pre-
diabetes; after 20 years, severe retinopa-
thy decreased 46%. Saaddine et al.
(abstract 382) reported retinopathy
prevalencesof34.2%among349persons
with known diabetes (10.5% had moder-
ate or severe nonproliferative retinopa-
thy, 2.8% had proliferative retinopathy,
and 4.1% had clinically signiﬁcant macu-
lar edema), 12.9% among 45 with previ-
ously undiagnosed diabetes, and 8.9%
among 361 with fasting plasma glucose
100and126mg/dlinthe2005–2006
NHANES. Retinopathy prevalences were
higher with longer duration of diabetes,
with higher A1C, and among persons
treatedwithinsulin.Weinrauchetal.(ab-
stract 867) treated 71 type 1 diabetic per-
sons with diabetic retinopathy and
nephropathy with glomerular ﬁltration
rate (GFR) 30 ml/min to weekly pulsa-
tile insulin infusion versus multiple daily
insulin dose treatment alone. Beneﬁt had
previously been shown in preservation of
renal function, but this was not demon-
strated for retinopathy; there was a trend
to reduced progression. Lee et al. (ab-
stract 945) reported that, among 1,241
type 2 diabetic patients, there was no as-
sociation of alcohol use with the presence
of diabetic retinopathy, but that regularly
drinking alcoholic beverages was associ-
ated with a 1.6- and 2.6-fold increase in
risk of deterioration of visual acuity over
mean 5.5-year follow-up among Cauca-
sian and non-Caucasian participants,
respectively.
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Current treatments. Willis et al. (ab-
stract 171) assessed cost-effectiveness of
the 2008 ADA/European Association for
the Study of Diabetes (EASD) consensus
statement approach for type 2 diabetes at
a goal A1C of 7% versus 8%. Following a
protocol of treatment with metformin,
then metformin plus sulfonylurea, then
metforminplusbasalinsulin,thenadding
prandial insulin three times daily, Willis
et al. calculated cost to be $3,610 higher
withthe7%targetanda$52,000costper
quality-adjusted life-year gained. Sensi-
tivity analysis showed “the 7% threshold
strategy would be more cost-effective if
treatment intensiﬁcation occurred with
therapies with better side-effect/
tolerability proﬁles.” Schramm et al. (ab-
stract 89) assessed 9,808 cardiovascular
deaths among 100,206 persons with dia-
betes living in Denmark initiating oral
agent monotherapy from 1997–2006.
Compared with metformin, mortality in-
creased among persons receiving glime-
peride, glibenclamide, glipizide, and
tolbutamide, trending to higher levels
with gliclazide and acarbose, and trend-
ing to lower levels in persons treated with
repaglinide. Jackness and Tamler (ab-
stract49-LB)createdalistofthetenmost-
prescribed medications in 2005–2006
among patients with diabetes from a da-
tabase of 91 health plans with 52 million
participants: metformin, statins, lisino-
pril, thiazolidinediones, furosemide, hy-
drochlorothiazide, insulin glargine,
amlodipine, and atenolol. For most of
these, 2- to 10-fold reductions in cost
were found in discount stores and mail-
order companies in comparison to neigh-
borhood retailers and convenience store
chains. Mathew et al. (abstract 532) in-
tenselytreated30type2diabeticpersons,
showing that insulin treatment reducing
fasting glucose from 164 to 89 mg/dl and
A1Cfrom9.0to7.3%wasassociatedwith
a 40% reduction in hepatic steatosis, with
no change in total body or intramyocellu-
lar fat.
Peroxisome proliferator–activated re-
ceptor–directed treatments. Gupta et
al. (abstract 8) found that peroxisome
proliferator–activated receptor (PPAR)-
signaling upregulated cultured islet glu-
cose-dependent insulinotropic peptide
(GIP)receptormRNAandproteinandin-
creased in vivo GIP-induced insulin se-
cretion. Reaven et al. (abstract 15-LB)
treated 393 persons with impaired glu-
cose tolerance with pioglitazone 45 mg
daily versus placebo for 39 months, ﬁnd-
ing a 0.006 versus 0.009 mm/year in-
crease in carotid intima-media thickness.
Perreault et al. (abstract 364) showed
greaterimprovementininsulinsensitivity
and in serum triglyceride and HDL cho-
lesterol levels in obese, insulin-resistant
adult rhesus monkeys receiving the bal-
anced pan PPAR agonist indeglitazar than
with pioglitazone, without the weight
gainseenwiththelatteragent.Delmedico
et al. (abstract 365) administered the
PPAR -	 and - agonist DB959 in animal
models of diabetes, reporting comparable
glycemic effect to that of rosiglitazone.
DePaoli et al. (abstract 117) treated 69
type 2 diabetic persons with INT131, a
selective PPAR- modulator, for 4 weeks,
showing a 30 mg/dl reduction in fasting
glucose with less weight gain and without
the hemodilution-related fall in hemato-
crit seen with thiazolidinediones.
D’Ardhuy et al. (abstract 924) adminis-
tered the PPAR-/ agonist aleglitazar
0–900 g daily for 6 weeks to 71 type 2
diabetic persons not receiving oral hypo-
glycemic agents, ﬁnding dose-dependent
improvement in glucose tolerance and
fasting glucose, insulin, triglyceride, and
HDL cholesterol levels. Henry et al. (ab-
stract 917) administered aleglitazar, pio-
glitazone, or placebo to 332 type 2
diabetic persons for 16 weeks, ﬁnding
dose-dependent improvement in A1C,
triglyceride, and LDL and HDL choles-
terol;edemawasseenathigheraleglitazar
doses. Yamaaki et al. (abstract 921) ad-
ministered both bezaﬁbrate and fenoﬁ-
brate to 10 dyslipidemic type 2 diabetic
patients, with both agents reducing tri-
glycerideandincreasingHDLcholesterol,
but only bezaﬁbrate increasing adiponec-
tin, reducing -glutamyl transpeptidase,
and improving glycemia, the authors
speculating it to be a dual / agonist.
Shi et al. (abstract 517) analyzed the
effect of warnings about thiazolidinedi-
oneusein2007on13,293type2diabetic
patients treated mainly with rosiglitazone
in the Veterans Affairs Health System.
A1C increased 0.3% in the 5,999 patients
discontinuing use of these agents, with
75% of these patients failing to take an-
other agent. Wang and Pugh (abstract
657) studied cardiovascular risk among
16,751 type 2 diabetic patients treated in
the Veteran’s Affairs system, ﬁnding no
evidence of harm with combined use of
rosiglitazone and insulin, indeed with re-
duction in cardiovascular risk among
some subgroups. Ma et al. (abstract 574)
reported lower costs of care for 407 per-
sonstreatedwithadditionofrosiglitazone
versus723withadditionofasulfonylurea
to metformin. Use of at least 80% of the
amount of medication prescribed was
demonstrated in 38% versus 27%. Simp-
son et al. (abstract 1,013) reported that
mortality among 297 and 906 diabetic
persons treated with metformin plus pio-
glitazone versus rosiglitazone was 1.22-
and 0.68-fold that of 1,902 diabetic per-
sons treated with metformin plus sulfo-
nylurea; neither of the risk ratios was,
however, signiﬁcantly different from
unity.
Lavery et al. (abstract 125) found 73,
50, and 12% greater foot, ankle, and hip
fracture rates in 45,319 diabetic than in
616,921 nondiabetic patients. Schwartz
et al. (abstract 985) compared fracture
riskamong520womenwithversus7,397
without self-reported type 2 diabetes, fol-
lowedfor5years,with256conﬁrmedhip
fractures. A T-score of 
2.5 was associ-
ated with a 6.1% 5-year fracture risk
among nondiabetic women at age 75, but
among diabetic women, the equivalent
riskwasseenwithaT-scoreof
2.0,sug-
gesting that this threshold be used for the
diagnosis of osteoporosis in diabetic pa-
tients. Aubert et al. (abstract 501) ana-
lyzed a pharmacy and medical claims
database of 13 million persons, with in-
formation on 69,047 persons receiving a
thiazolidinedione and 75,352 compara-
tors,takingmetformin,exenatideorasul-
fonylurea. Controlling for age; for
diagnoses of COPD, asthma, osteoporo-
sis, and stroke; and for prior fracture,
fractures were 55% more likely for
women and 26% more likely for men
treated with a thiazolidinedione, without
difference between rosiglitazone and
pioglitazone.
Novel treatments. Huffman et al. (ab-
stract326)studiedHNGF6A,ananalogof
Humanin, which has been evaluated for
neuroprotection in studies of Alzheimer’s
disease–relatedneurotoxicityinZDFrats.
HNGF6A improved insulin sensitivity
and lowered blood glucose levels. Scran-
tonetal.(abstract481)assessedtheeffect
of rapidly absorbed bromocriptine versus
placebo in 113 thiazolidinedione-treated
patientswithA1C7.5%,ﬁndinga0.7%
versus 0.6% A1C reduction over 52
weeks. Gumbiner et al. (abstract 11-LB)
administered MB07803, a fructose-1,6-
bisphosphatase inhibitor, to 42 type 2 di-
abetic persons with baseline A1C 8.8%
andfastingglucose221mg/dlfor14days,
demonstrating 16, 58, and 55 mg/dl re-
ductions in fasting glucose with 50, 200,
and 400 mg daily, respectively. One-third
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half of those receiving 400 mg developed
vomiting,withonepersondevelopingnon-
sustainedlactate4.5mmol/l.Migoyaetal.
(abstract116)administeredtheglucokinase
activator MK-0599 in doses of 25, 50, and
100 mg three times over a 1-day period to
nondiabetic persons, ﬁnding dose-related
glucose-lowering but with hypoglycemia at
two higher doses.
Glucocorticoid antagonism. Rosen-
stock et al. (abstract 7-LB) administered
the 11--hydroxysteroid dehydrogenase
type 1 inhibitor, INCB13739, to met-
formin-treated type 2 diabetic patients,
ﬁnding no change in A1C in 28 patients
receiving placebo, but 0.6% and 0.5% re-
ductions in 54 patients receiving 100 and
200 mg daily, respectively. Plasma ACTH
increased but remained within the nor-
mal range, and cortisol levels were un-
changed, suggesting that adrenal
insufﬁciency would not occur frequently
with this agent (but that it could occur).
Asagami et al. (abstract 92-LB) adminis-
tered a selective glucocorticoid antago-
nist, ADS108297, not affecting
progesterone action, to mice in a diet-
induced obesity model, showing preven-
tion of weight gain and a similar
improvement of insulin resistance to that
seen with rosiglitazone administration.
Gross et al. (abstract 97-LB) administered
the glucorticoid receptor antagonist mife-
pristone 600 mg daily or placebo to 60
persons treated with risperidone 1.5–2.0
mgtwicedaily,ﬁndinga2.3versus4.2kg
weight gain at 28 days with prevention of
increased fasting insulin and triglyceride
levels.
Anti-inﬂammatory treatments. Do-
nath et al. (abstract 113) showed a 1.1%
A1C reduction at 3 months in type 2 dia-
betic patients following a 0.1 mg/dl single
infusion of the high-afﬁnity anti-
interleukin-1 antibody XOMA 052.
Owang et al. (abstract 310) reported sim-
ilar effects in a high-fat/high-sucrose diet
diabetic mouse model. Boaz et al. (ab-
stract 1,724) compared 100 type 2 dia-
betic patients who had lost weight with
102 patients who had no weight loss his-
tory, ﬁnding that 89% versus 72% had
taken anti-inﬂammatory agents, with ex-
posure to these agents more than dou-
bling the likelihood of weight loss.
Goldﬁne et al. (abstract 115) treated 108
type 2 diabetic persons having A1C 7.0–
9.5% with the NF-B inhibitor salsalate,
3, 3.5, or 4.0 g three times daily, ﬁnding
placebo-adjusted 0.5–0.6% reduction in
A1C, 27–32 mg/dl reduction in fasting
glucose, 31–49 mg/dl reduction in tri-
glyceride,and1.7–2.8g/mlelevationin
adiponectin, with hypoglycemia in pa-
tients receiving concomitant sulfonyl-
ureas; 20% versus 11% of placebo-
receiving patients developed tinnitus.
Han et al. (abstract 360) administered
600mg/dayof-lipoicacidintravenously
for14daysto10overweightpersonswith
IGT and 6 with normal glucose tolerance,
showingimprovementininsulinsensitiv-
ity and -cell function with treatment.
Schwartz et al. (abstract 362) adminis-
tered the antioxidant bardoxolone to 57
diabetic persons with chronic kidney dis-
ease, showing a 0.3% reduction in A1C
from a baseline of 7.6%.
Bile acid–directed treatments. Beysen
et al. (abstract 476) performed glucose
turnoverstudiesin55type2diabeticper-
sons randomized to colesevelam 3.75 g
daily or placebo, showing 0.5% and 20
mg/dl differences in A1C and fasting glu-
cose after 12 weeks. Insulin levels did not
change, glucose production increased
with placebo while not changing with
colesevelam, and glucose clearance in-
creased with colesevelam while not
changing with placebo, suggesting this to
be the mechanism of the glucose-
lowering effect of the agent. Brufau et al.
(abstract 498) studied bile acid pool sizes
andsynthesisratesin12normalandin12
type2diabeticpersonsbeforeandafteran
8-week period of administration of
colesevelam. At baseline, the diabetic pa-
tients had higher cholic acid synthesis
rate, higher deoxycholic acid input rate
and pool size, higher percent contribu-
tions to the total bile acid pool and lower
chenodeoxycholic acid pool sizes.
Colesevelam reduced A1C by 0.65% and
increased the cholic acid pool size in the
diabetic patients, leading to increased hy-
drophilicityofthebileacidpooland,pre-
sumably, to reduced susceptibility to
gallstone formation. Triglyceride levels
increased 40 mg/dl, correlating with the
increase in cholic acid synthesis, and LDL
cholesterol decreased 11 mg/dl. Takeba-
yashi et al. (abstract 503) compared ef-
fectsofcolestimide3.0gandrosuvastatin
2.5mgdailyin40type2diabeticpersons
with dyslipidemia, ﬁnding the former to
reduce A1C from 8.8 to 7.9%, as well as
urinary levels of 8-iso-prostaglandin F2
and monocyte chemoattractant pro-
tein-1, without inﬂuencing insulin sensi-
tivity, adiponectin, or retinol binding
protein-4 levels. Henry et al. (abstract 13-
LB) treated 64 type 2 diabetic patients
with nonalcoholic fatty liver with 6-ethyl
chenodeoxycholic acid, INT-747, a po-
tent farnesoid-X receptor (FXR) agonist,
25 or 50 mg daily for 6 weeks. Glucose
disposal rate decreased 6% with placebo,
whereas it increased 20–30% with low-
dose insulin and 10–20% with high-dose
insulin; liver chemistries improved; and
LDL increased with a reduction in HDL
cholesterol and triglyceride levels. One
should note the paradox that bile acid se-
questrants, by lowering bile acid levels,
reduce their activation of FXR, and hence
reduce FXR activation, which has been
thought to lead to lower glucose levels
(25), yet the modiﬁed bile acid, which
activates FXR, was demonstrated to have
a glucose-lowering effect as well.
Treatments increasing glycosuria.
Wilding et al. (abstract 482) treated 71
insulin-requiring type 2 diabetic patients
with placebo versus dapagliﬂozin. Dapa-
gliﬂozin blocks renal glucose reabsorp-
tion by selectively inhibiting sodium-
glucose cotransporter 2. Administration
ofdapagliﬂozinresultedinanA1Creduc-
tionof0.1%versus0.6%withweightloss
of 1.9 versus 4.4 kg over 12 weeks. Chari
et al. (abstract 110) normalized glucose
with use of phlorizin to produce glycos-
uria in a streptozotocin-diabetic rat
model,showingrestorationofresponseto
mediobasal hypothalamic hypoglycemia,
with the glial isoform of GLUT1 reduced
by 50% with hyperglycemia and return-
ing to normal levels with treatment.
Pramlintide. Lutz et al. (abstract 579)
andPenceketal.(abstract580)presented
observationalopen-label6-monthstudies
of the effects of pramlintide in 541 type 1
and 364 type 2 diabetic persons receiving
prandial insulin (70% of those beginning
the studies). Type 1 diabetic patients
completing the study reduced prandial
insulin by 14%, increased long-acting in-
sulin 8%, lost 2.8 kg weight, and had a
0.3% reduction in A1C. Type 2 diabetic
patients completing the study increased
insulin16%,lost1.9kgweight,andhada
0.5% reduction in A1C. Hypoglycemia
requiring assistance occurred at rates of
33% and 8% per year during 0–3 and
3–6 months, respectively, in type 1 dia-
betic patients and at rates of 19% and 2%
per year in type 2 diabetic patients.
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